Our Team

Each Partner brings extensive industry knowledge, unrivaled relationships and substantial deal experience, resulting in a team of the industry's most sought after advisors

Andrew S. Rymer

Andrew Rymer is a Partner in Centerview’s healthcare investment banking team. He brings over 20 years of experience, advising companies on a variety of strategic matters.

Mr. Rymer has established himself as one the leading healthcare M&A advisors, having worked on some of the industry’s largest and most important transactions, including:

Large Pharma - Advised Pfizer in multiple transactions including its $68bn acquisition of Wyeth; its $14bn acquisition of Medivation; its $5bn acquisition of Anacor; and its $18bn OTC JV with Glaxo; Merck in its $3bn acquisition of Antelliq; its spinoff of its Organon division; and its worldwide strategic collaboration with Eisai regarding Lenvima; Johnson & Johnson in its $21bn acquisition of Synthes; Novartis in its $1bn sale of its Sandoz US dermatology and generics business to Aurobindo

Biotech – Advised Iveric in its $5.9bn sale to Astellas; Endocyte in its $2.1bn sale to Novartis; CTI Biopharma in its $1.7bn sale to Sobi; Gyroscope Therapeutics in it’s up to $1.5bn sale to Novartis; Micromet in its $1.2 billion sale to Amgen; NeuroDerm in its $1.1bn sale to Mitsubishi Tanabe; Nightstar Therapeutics’ in its $877mm sale to Biogen; ITeos in its development and commercialization collaboration with GSK regarding EOS-448 ($625mm upfront + milestones and royalties); Arctos Medical in its sale to Novartis; Adverum on its successful 2021 activist defense; LogicBio in its sale to Alexion (largest biotech premium of all time); Chimerix in its sale of TEMBEXA to Emergent BioSolutions

Pharma Services / CMO – Advised Catalent in its $1.2bn acquisition of Paragon Bioservices and $1bn acquisition of Bettera Brands; Kohlberg in its $3bn acquisition of PCI Pharma Services and its acquisition of Trinity Life Sciences; inVentiv in its $1.1 billion sale to TH Lee; Mayne Pharma in its $475mm sale of Metrics Contract Services to Catalent; Casdin / Viking in their investment in Fluidigm to create Standard BioTools; Phillip-Medisize in its sale to Golden Gate Capital

Healthcare Services – Advised Blackstone, Carlyle and Hellman & Friedman on their $34bn acquisition of Medline Industries; athenahealth in $5.7bn sale to Veritas Capital and Evergreen Coast Capital; US Renal in its sale to Leonard Green

Additionally, Mr. Rymer has executed numerous financing transactions and advisory assignments for a diverse group of industry leaders including Pfizer, Johnson & Johnson, Eli Lilly, Aetna, Wellchoice, Horizon Blue Cross Blue Shield and many of the largest financial sponsors.

Prior to joining Centerview, Mr. Rymer spent 10 years at Goldman Sachs, most recently as a Managing Director with responsibility for the firm’s Healthcare M&A activities. While at Goldman Sachs, he was asked by the firm’s CEO and President to serve as Head of Client Strategy for 18 months in order to help enhance effectiveness across Goldman’s client footprint. Mr. Rymer began his career as an investment banking analyst at Donaldson, Lufkin & Jenrette and worked at Credit Suisse upon its acquisition of DLJ.

Mr. Rymer received a B.A., cum laude and with Honors, from Dartmouth College. Mr. Rymer lives in New York City with his wife and three children.
Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

Centerview is honored to partner with leading charitable organizations in active support of our charities:

  • Arts Connection
  • NY Cares
  • Bottomless Closet
Syneos Health, Inc
Announced: Q2 2023
Value: $7.1 billion
Status: Pending

Lead financial advisor to Syneos Health on its sale to a private investment consortium comprised of Elliott Investment Management, Patient Square Capital and Veritas Capital
View All
New York

Centerview Partners LLC

31 West 52nd Street

22nd Floor

New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax

Centerview Partners UK LLP

100 Pall Mall

3rd Floor

London SW1Y 5NQ

02074099700 | Tel
02074099704 | Fax

Centerview Partners France SCS

16 Avenue Matignon

4th Floor

Paris 75008

0180200620 | Tel
0180200621 | Fax
Palo Alto

Centerview Partners LLC

600 Ramona St.

Suite 300

Palo Alto, California 94301

(650) 822-5800 | Tel
(650) 822-5801 | Fax
San Francisco

Centerview Partners LLC

555 California Street

Suite 4300

San Francisco, California 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax

Copyright © 2008 - 2023 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC